Literature DB >> 27177498

SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.

Claire Douillard1, Pascal Houillier2, Juerg Nussberger3, Xavier Girerd4.   

Abstract

In patients with suspected primary aldosteronism (PA), the first diagnostic step, screening, must have high sensitivity and negative predictive value. The aldosterone-to-renin ratio (ARR) is used because it has higher sensitivity and lower variability than other measures (serum potassium, plasma aldosterone, urinary aldosterone). ARR is calculated from the plasma aldosterone (PA) and plasma renin activity (PRA) or direct plasma renin (DR) values. These measurements must be taken under standard conditions: in the morning, more than 2hours after awakening, in sitting position after 5 to 15minutes, with normal dietary salt intake, normal serum potassium level and without antihypertensive drugs significantly interfering with the renin-angiotensin-aldosterone system. To rule out ARR elevation due to very low renin values, ARR screening is applied only if aldosterone is>240pmol/l (90pg/ml); DR values<5mIU/l are assimilated to 5mIU/l and PRA values<0.2ng/ml/h to 0.2ng/ml/h. We propose threshold ARR values depending on the units used and a conversion factor (pg to mIU) for DR. If ARR exceeds threshold, PA should be suspected and exploration continued. If ARR is below threshold or if plasma aldosterone is<240pmol/l (90pg/ml) on two measurements, diagnosis of PA is excluded.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aldosterone; Aldosterone-to-renin ratio (ARR); Aldostérone; Conditions standardisées; Dépistage; Hyperaldostéronisme primaire; Primary aldosteronism; RAR; Rapport aldosterone/rénine; Renin; Rénine; Screening; Standard conditions

Mesh:

Substances:

Year:  2016        PMID: 27177498     DOI: 10.1016/j.ando.2016.02.003

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  6 in total

Review 1.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  Medication adherence during laboratory workup for primary aldosteronism: pilot study.

Authors:  Friederike A Sandbaumhüter; Manuel Haschke; Bruno Vogt; Jürgen M Bohlender
Journal:  Patient Prefer Adherence       Date:  2018-11-19       Impact factor: 2.711

3.  The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal.

Authors:  Zhe Meng; Liang Zhou; Zhe Dai; Chang Xu; Guofeng Qian; Mou Peng; Yuchun Zhu; Joey S W Kwong; Xinghuan Wang
Journal:  Front Med (Lausanne)       Date:  2020-05-05

Review 4.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17

Review 5.  How to Explore an Endocrine Cause of Hypertension.

Authors:  Jean-Baptiste de Freminville; Laurence Amar
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

6.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.